NeoStem Announces Appointment of Three Acclaimed Business and Media Professionals to Stem for Life Foundation Board of Directors.

New Directors to Focus on Mission of Advancing Public Awareness and Making Stem Cell Science and Services Available to Nation's First Responders

NEW YORK -- NeoStem, Inc. (AMEX:NBS), the first company to specialize in the collection, processing and long term storage of stem cells from healthy adults for personal use in times of critical medical need, has announced the appointment of three new independent members to the Board of Directors of the Stem for Life Foundation (SFLF). SFLF, whose SS501(c )(3) designation as a not-for-profit organization is pending, was recently founded by NeoStem. The newly named independent directors include prominent professionals from the biological sciences, journalism, media, business and finance.

NeoStem recently launched the "Stem for Life" Foundation, dedicated to heightening public awareness of the benefits and the promise of utilizing adult stem cells to treat serious medical conditions in the burgeoning regenerative medicine industry.

The newly appointed board of independent directors will devote their energies to helping to make adult stem cell therapies and treatments available to the public through special programs aimed at assisting the nation's first responders and public safety professionals, including firefighters, police and military personnel.

The newly named directors are:

* Max Gomez, Ph.D. Dr. Gomez joined WCBS-TV in New York City in July 2007. Previously, he was the Health and Science Editor at News Channel 4. Dr. Gomez has received six New York Emmy Awards, two Philadelphia Emmys and a UPI honor for Best Documentary. In addition, he was named the American Health Foundation's Man of the Year and was a NASA Journalist-In-Space semi-finalist in 1986. Dr. Gomez, a native of Havana, Cuba, is bilingual in Spanish and graduated cum laude from Princeton University. He received his Ph.D. from the Bowman Gray School of Medicine and was an N.I.H. Postdoctoral Fellow at New York's Rockefeller University.

* Thomas L. Harrison, Lh.D. Mr. Harrison is Chairman and Chief Executive Officer of Diversified Agency Services (DAS), the world's largest group of marketing services companies, a division of the Omnicom Group. He has an advanced degree in cell biology and physiology and is a frequent speaker at business forums and universities on the subject of entrepreneurialism and is the author of the recently published book INSTINCT.

* Neil Rubin. Mr. Rubin has twenty-one years of experience in the financial services industry and is a Senior Vice President of Investments with Oppenheimer & Co. Inc. Prior to joining Oppenheimer, he was in the wealth management division of Bluestone Capital Partners. Mr. Rubin began his career at Lehman Brothers.

SFLF's Board of Directors is still in formation and more appointments are anticipated. SFLF is also forming honorary boards of advisors focused on a diverse set of disciplines. These advisors will provide the Foundation with unique expertise and added opportunities to further its objectives.

SFLF plans to mount a high-profile campaign to protect the health of the nation's first responders by assisting them in the collection and storage of their own autologous stem cells for potential recovery following exposure to harmful nuclear, biological, chemical or radiological environments, burns, diseases, emergencies and combat-related injuries. Additionally, SFLF plans to provide the resources to make adult stem cell collection widely available to chronically ill patients in need of the service but who are unable to pay for it.

About NeoStem, Inc.

NeoStem is a biotechnology services company enhancing the delivery of adult stem cell therapeutics to health-conscious consumers. The Company is developing a nationwide network of adult stem cell collection centers, enabling people to donate and store their own stem cells with NeoStem for personal use years or decades later in times of critical medical need. Although adult stem cell therapies are generally not standard of care, the Company believes medicine is on the threshold of a plethora of such new therapies.

The proprietary NeoStem technologies empower health-conscious consumers to help protect their future health by undergoing treatment with their own stem-cells - providing an accessible supply of healthy, genetically matched stem cells for use in the eventuality of illness.

Currently underway are hundreds of stem cell-based research programs and clinical trials investigating the use of these non-controversial adult stem cells, such as those collected from donors under NeoStem's methods. As the nation's population ages and encounters serious age-related and congenital health issues, NeoStem has positioned itself as a leader in the national trend toward protecting one's future health.

The Company's business plan is a service model that is completely scalable, thus minimizing risk levels ordinarily related to most long-term biopharmaceutical research and development. Under its strategic business plan, NeoStem has begun opening a nationwide network of adult stem cell collection facilities. Its stem cell collection systems will be located in existing physician offices and medical facilities, where the procedures and care can be administered by trusted personal doctors and medical professionals.

For more information, please visit: www.neostem.com.

For other information and resources about the Company, visit www.CFSG1.com or www.trilogy-capital.com/tcp/neostem/quote.html.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, the future of regenerative medicine and the role of adult stem cells in that future, the future use of adult stem cells as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena, its success in such arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control; (v) the Company's inability to obtain appropriate state licenses or any other adverse effect or limitations caused by government regulation of the business; (vi) whether any of the Company's current or future patent applications result in issued patents; and (vii) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at www.sec.gov under "Search for Company Filings."

Pursuant to an October 1, 2006 agreement, Consulting For Strategic Growth I, Ltd. ("CFSG1") provides the Company with consulting, business advisory, investor relations, public relations and corporate development services, for which CFSG1 receives a fixed monthly fee for the duration of the agreement and received shares of NeoStem's common stock. Independent of CFSG1's receipt of cash or other compensation from the Company, CFSG1 may choose to purchase the common stock of the Company and thereafter sell those shares at any time it deems appropriate to do so. For more information, please visit www.cfsg1.com.